Page last updated: 2024-08-05 11:11:19

pyranoindolizinoquinoline

null

ChEBI ID: 48626

Members (12)

MemberDefinitionRole
10-hydroxycamptothecin10-Hydroxycamptothecin
7-ethylcamptothecin7-ethylcamptothecin
9-aminocamptothecin9-Aminocamptothecin
belotecanbelotecan
camptothecinA pyranoindolizinoquinoline that is pyrano[3',4':6,7]indolizino[1,2-b]quinoline which is substituted by oxo groups at positions 3 and 14, and by an ethyl group and a hydroxy group at position 4 (the S enantiomer).camptothecin
cositecancositecan
dx 8951exatecan
irinotecanA member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active.irinotecan
LSM-1442LSM-1442
rubitecanA pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.rubitecan
sn 38A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself.SN-38
topotecanA pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.topotecan

Research

Studies (15,686)

TimeframeStudies, Drugs in This Class (%)All Drugs %
pre-1990233 (1.49)18.7374
1990's1,696 (10.81)18.2507
2000's5,640 (35.96)29.6817
2010's6,198 (39.51)24.3611
2020's1,919 (12.23)2.80

Study Types

Publication TypeStudies, Drugs in This Class (%)All Drugs (%)
Trials4,865 (20.05%)5.53%
Reviews2,799 (11.54%)6.00%
Case Studies1,709 (7.04%)4.05%
Observational113 (0.47%)0.25%
Other14,774 (60.90%)84.16%